Stock Analysts

Nokia (NOK) to Report Q4 Earnings: What’s in the Offing?

Nokia Corporation NOK is scheduled to report fourth-quarter 2017 financial numbers on Feb 1. Last quarter, the company reported earnings (non-IFRS) per share of €0.09 (approximately 11 cents) that surpassed the Zacks Consensus Estimate of 6 cents. In the year-ago period, the company had reported earnings of €0.04 (5 cents) per share. […]

Stock Analysts

Auto Stocks Q4 Earnings: Key Forecast for PCAR, HOG & More

With fourth-quarter results getting released across all sectors, a few companies under the Auto sector have posted financial numbers. Two auto giants, Ford Motor Company F and Fiat Chrysler Automobiles FCAU , have already announced quarterly performance on Jan 25. While Ford’s earnings missed the Zacks Consensus Estimate, Fiat Chrysler beat the same. […]

Stock Analysts

Glaxo’s Shingles Vaccine Shingrix Gets Positive CHMP Opinion

Glaxo SmithKline plc GSK announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has a positive opinion, recommending a marketing approval for its shingles vaccine, Shingrix. A final decision from the EU is expected in April 2018. The company filed a marketing authorization application for Shingrix in the EU for prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN) in older patients (aged 50 years or above) in November 2016 […]

Stock Analysts

AstraZeneca’s Triple Combo COPD Inhaler Positive in Phase III

AstraZeneca Plc AZN announced positive top-line results from a phase III study evaluating its investigational triple combination therapy PT010 for the treatment of chronic obstructive pulmonary disease (COPD). PT010 is a combination of budesonide, an ICS with glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a LABA therapy. PT010 is being developed by delivering AstraZeneca’s Aerosphere Delivery Technology […]